Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting
"Presenting data highlighting the performance of our Target Selector™ assays, kits, and blood collection tubes at major scientific and medical conferences, such as this year's AMP Annual Meeting, is important for driving awareness and adoption of our industry leading testing platform," said
Poster presentation details are as follows:
Title: Mutant-p53 antibody stains cytokeratin negative CTCs enriched and detected with a "Pan-CTC" antibody cocktail
Session Category: Hematopathology
Session Date and Time: Friday November 8, 2019,
Location: Exhibit Hall, Poster Number H015
Title: Monitoring Breast Cancer Biomarkers from Circulating Tumor DNA using Target Selector NGS Breast Panel
Session Category: Solid Tumors
Session Date and Time: Friday November 8, 2019 -
Location: Exhibit Hall, Poster Number ST048
Title: Highly Sensitive and Specific Detection of a Cytokeratin Positive and Negative Circulating Tumor Cells
Session Category: Solid Tumors
Session Date and Time: Friday November 8, 2019 -
Location: Exhibit Hall, Poster Number ST052
Title: Target Selector DNA EGFR kit for tissue demonstrates high sensitivity without the need for macro-dissection
Session Category: Genetics
Session Date and Time: Saturday November 9, 2019 -
Location: Exhibit Hall, Poster Number G021
Title: Validation of
Session Category: Solid Tumors
Session Date and Time: Saturday November 9, 2019 -
Location: Exhibit Hall, Poster Number ST049
Title: Detection of Potential Epithelial Mesenchymal Transition Cells in Localized Prostate Cancer
Session Category: Solid Tumors
Session Date and Time: Saturday November 9, 2019 -
Location: Exhibit Hall, Poster Number ST053
About the
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to our ability to improve the management, diagnosis and treatment of cancer, and the ability of our tests to provide clinically actionable information to oncologist and their patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-tests-and-kits-to-be-featured-in-six-poster-presentations-at-the-2019-association-for-molecular-pathology-annual-meeting-300948057.html
SOURCE